GCK
Reactivity: Human
WB, IF
Host: Mouse
Polyclonal
unconjugated
Application Notes
Western Bloting: 1/500 - 1/2000. ELISA: Propose dilution 1/10000. Not yet tested in other applications. Determining optimal working dilutions by titration test.
Restrictions
For Research Use only
Format
Liquid
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C
Barbetti, Cobo-Vuilleumier, Dionisi-Vici, Toni, Ciampalini, Massa, Rodriguez-Bada, Colombo, Lenzi, Garcia-Gimeno, Bermudez-Silva, Rodriguez de Fonseca, Banin, Aledo, Baixeras, Sanz, Cuesta-Muñoz: "Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene." in: Molecular endocrinology (Baltimore, Md.), Vol. 23, Issue 12, pp. 1983-9, (2009) (PubMed).
Yoshida, Kato, Yokoi, Oguri, Watanabe, Metoki, Yoshida, Satoh, Aoyagi, Nishigaki, Nozawa, Yamada: "Association of genetic variants with chronic kidney disease in individuals with different lipid profiles." in: International journal of molecular medicine, Vol. 24, Issue 2, pp. 233-46, (2009) (PubMed).
Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. Alternative splicing of this gene results in three tissue-specific forms of glucokinase, one found in pancreatic islet beta cells and two found in liver. The protein localizes to the outer membrane of mitochondria. In contrast to other forms of hexokinase, this enzyme is not inhibited by its product glucose-6-phosphate but remains active while glucose is abundant. Mutations in this gene have been associated with non-insulin dependent diabetes mellitus (NIDDM), maturity onset diabetes of the young, type 2 (MODY2) and persistent hyperinsulinemic hypoglycemia of infancy (PHHI). Synonyms: GK, GLK, HK4, HHF3, HKIV, HXKP, LGLK, MODY2, FGQTL3